CreditRiskMonitor is a financial risk analysis and news service for credit, supply chain and financial professionals.  Our strength in coverage spans 58,000 global public companies, totaling about $70 trillion in corporate revenue.  We also offer solutions that can help ease private company financial risk assessment.  Leading corporations around the world – including more than 35% of the Fortune 1000, plus thousands more worldwide – rely on us to help them stay ahead of financial risk quickly, accurately and cost-effectively. 

A partial report preview for QuantaMatrix Inc is shown below.  Where indicated by "Yes," CreditRiskMonitor contains this information in its extensive database.  To get access to the full report and learn more about CreditRiskMonitor's robust financial risk analysis and timely news service, request a personalized demo and free trial today.

If you are already a subscriber and want to access the full report, click here.

QuantaMatrix Inc
16F, B Dong, BYC HIGHCITY, 131
Gasan digital 1-ro, Geumcheon-gu
Phone: +82 269563458p:+82 269563458 SEOUL, 08506  South Korea Ticker: 317690317690
Business Summary
QuantaMatrix Inc is a Korea-based company principally engaged in the development and production of in vitro diagnostic (IVD) medical devices business. The Company primarily conducts research and development, manufactures, and sells IVD medical devices that utilize substances collected from the human body, such as blood, feces, body fluids, and saliva, to hospitals and contract testing institutions. In addition, the Company develops in vitro diagnostic devices for sepsis and bacteremia antimicrobial susceptibility testing based on microbial diagnostic technology and develops medical devices for early diagnosis and prognosis prediction of various diseases based on its own molecular immunodiagnostic testing platform.

Scores and Ratings
FRISK®
Score		 Z''
Score		 PAYCE®
Score		 DBT
Index		 Moody's
Rating		 Fitch
Rating		 DBRS
Rating
YesYes-Yes---

Financials, News and Filings
Latest
Statement		 Last
Audit
News		 SEC
Filings		 Bankruptcy
Filings		 Suit &
Judgment
Filings		 Tax
Lien
Filings
12/31/202412/31/2024Yes----

Industries
SIC Code Description
2835 In vitro and in vivo diagnostic substances

Officers and Directors

Title
Name
Age		 Title
Date		 Start
Date
Chief Executive Officer, Director Seong HunGwon 47
Deputy Chief Executive Officer, Chief Financial Officer, Director Jae HunGwon 46
Deputy Chief Executive Officer, Chief Technology Officer, Director Dong YeongKim 48
Internal Auditor Jae HyeonGwon 51
Non-Executive Independent Director Won HuiSul 62

General Information
Number of Employees: 95 (As of 3/31/2024)
Outstanding Shares: 18,144,289 (As of 3/27/2025)
Shareholders: 15,858
Stock Exchange: KDQ
Fax Number: +82 27638650


Copyright © 2025 CreditRiskMonitor.com (Ticker: CRMZ). All rights reserved.     
By using this website, you accept the Terms of Use Agreement.
Tuesday, April 8, 2025